MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Lista de Ações・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Fechado

SetorSaúde

33.75 -0.21

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

33.24

Máximo

33.9

Indicadores-chave
By Trading Economics
Rendimento	-14M -81M
Vendas	75K 75K
EPS	-1.22
Margem de lucro	-108,422.667
Funcionários	198
EBITDA	-7.8M -81M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+60.91% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	941M 2.6B
Abertura anterior	33.96
Fecho anterior	33.75

Sentimento de Notícias

By Acuity

100%

337 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

18.91 / 20.63 Suporte e Resistência

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de abr. de 2026, 23:26 UTC

Ações em Alta

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 de abr. de 2026, 20:41 UTC

Grandes Movimentos do Mercado

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 de abr. de 2026, 23:49 UTC

Conversa de Mercado

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 de abr. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Decline After Hitting Record High -- Market Talk

16 de abr. de 2026, 23:33 UTC

Conversa de Mercado

Notícias Principais

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 de abr. de 2026, 22:51 UTC

Conversa de Mercado

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 de abr. de 2026, 22:08 UTC

Ganhos

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Tech, Media & Telecom Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Notícias Principais

Basic Materials Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Health Care Roundup: Market Talk

16 de abr. de 2026, 20:49 UTC

Ganhos

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 de abr. de 2026, 20:43 UTC

Ganhos

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 de abr. de 2026, 20:40 UTC

Conversa de Mercado

Ganhos

Global Equities Roundup: Market Talk

16 de abr. de 2026, 20:40 UTC

Conversa de Mercado

Ganhos

Netflix Says Engagement Quality Hits New High -- Market Talk

16 de abr. de 2026, 20:30 UTC

Ações em Alta

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 de abr. de 2026, 20:25 UTC

Ganhos

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 de abr. de 2026, 20:23 UTC

Ganhos

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 de abr. de 2026, 20:19 UTC

Ganhos

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 de abr. de 2026, 20:17 UTC

Ganhos

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 de abr. de 2026, 20:17 UTC

Ganhos

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

60.91% parte superior

Previsão para 12 meses

Média 54.5 USD 60.91%

Máximo 90 USD

Mínimo 24 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Recent bullish events outweigh bearish events.

All events are bearish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.